Online inquiry

IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5417MR)

This product GTTS-WQ5417MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD74 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001025158.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 972
UniProt ID P04233
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5417MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4689MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ3621MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ8419MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HSP90mab
GTTS-WQ12525MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ1542MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACE-031
GTTS-WQ5311MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ2196MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ7700MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GEXMab73
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW